I think we will see a merger announced between Humanigen and Sanofi (HSAI).
I'm not sure of how the UPenn agreement with PolyMedix is relevant. PolyMedix went bankrupt after developing Brilacidin. The IP rights went to our predecessor company and now IPIX has the IP. Or, more accurately, perhaps I should say they HAD the IP. I think the Brilacidin IP has been sold to HSAI.